Affiliation:
1. Bayer Pharmaceuticals Berkeley California USA
Abstract
AbstractBiopharmaceutical manufacturing entails a series of highly regulated steps. The manufacturing of safe and efficacious drug product (DP) requires testing of critical quality attributes (CQAs) against specification limits. DP potency concentration, which measures the dosage strength of a particular DP, is a CQA of great interest. In order to minimize the DP potency out‐of‐specification (OOS) risk, sterile fill finish (SFF) process adjustments may be needed. Varying the potency targets can be one such process adjustment. To facilitate such evaluation, data acquisition and statistical calculations are required. Regularly conducting the OOS risk assessment manually using commercial statistical software can be tedious, error‐prone, and impractical, especially when several alternate potency targets are under consideration. In this work, the development of a novel framework for OOS risk assessment and deployment of cloud‐based statistical software application to facilitate the risk assessment are presented. This application is intended to streamline the assessment of alternate potency targets for DP in biologics manufacturing. The major aspects of this potency targeting application development are presented in detail. Specifically, data sources, pipeline, application architecture, back‐end and front‐end development as well as application verification are discussed. Finally, several use cases are presented to highlight the application's utility in biologics manufacturing.
Reference13 articles.
1. CFR—Code of federal regulations title 21: database.2023https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=314.3
2. US FDA.Q8(R2) Pharmaceutical Development. United States Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) editors.2009.
3. Protein formulation and fill-finish operations
4. Wang W.Potency testing of biopharmaceutical products.2014;https://www.americanpharmaceuticalreview.com/Featured-Articles/169473-Potency-Testing-of-Biopharmaceutical-Products/.
5. US FDA.Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. United States Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Drug Evaluation and Research (CDER) editors.1999.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献